Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PRKCI | P41743 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | XDH | P47989 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7008038 | 0.75 | HSD17B10 (0.47) | HSD17B10ALDH1A1TDP1PARP1PRKCI | |
| SCHEMBL5142749 | 0.75 | NOS1 (0.42) | HSD17B10ALDH1A1TDP1PARP1PRKCI | |
| SCHEMBL13485029 | 0.68 | ALDH1A1 (0.36) | HSD17B10ALDH1A1TDP1PARP1PRKCI | |
| Phthalazinone SCHEMBL51553 | 0.67 | PARP1 (1.00) | HSD17B10ALDH1A1TDP1PARP1PRKCI | |
| Phthalazinone SCHEMBL2473799 | 0.66 | PARP1 (0.96) | HSD17B10ALDH1A1TDP1PARP1PRKCI | |
| Phthalazinone SCHEMBL9617397 | 0.66 | PARP1 (0.96) | HSD17B10ALDH1A1TDP1PARP1PRKCI | |
| Phthalazinone SCHEMBL11516881 | 0.66 | PARP1 (0.96) | HSD17B10ALDH1A1TDP1PARP1PRKCI | |
| Phthalazinone SCHEMBL11519244 | 0.66 | PARP1 (0.96) | HSD17B10ALDH1A1TDP1PARP1PRKCI | |
| Phthalazinone SCHEMBL11690359 | 0.66 | PARP1 (0.96) | HSD17B10ALDH1A1TDP1PARP1PRKCI | |
| SCHEMBL22829565 | 0.66 | ALDH1A1 (0.52) | HSD17B10ALDH1A1TDP1PARP1PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109896-A1 | FGFR KINASE INHIBITOR AND USE THEREOF | YA THERAPEUTICS INC (CN) | 2024-04-04 | — | — | US | claimed |
| EP-1296982-A1 | 1-(HETEROARYL-PHENYL)-CONDENSED PYRAZOL DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-04-02 | — | — | EP | claimed |
| WO-2002000655-A1 | 1 - (HETEROARYL-PHENYL) - CONDENSED PYRAZOL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-03 | — | — | WO | claimed |
| CN-115433190-B | Preparation method and application of irreversible heterocyclic compound FGFR inhibitor | 药雅科技(上海)有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-115433190-A | Preparation method and application of irreversible heterocyclic compound FGFR inhibitor | 药雅科技(上海)有限公司 | 2022-12-06 | — | — | CN | disclosed |
| WO-2022166469-A1 | FGFR KINASE INHIBITOR AND USE THEREOF | 药雅科技(上海)有限公司 | 2022-08-11 | — | — | WO | disclosed |
| WO-2015189433-A1 | PYRIDAZINONES FOR THE TREATMENT OF CANCER | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-17 | — | — | WO | disclosed |
| EP-2137158-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES (PRMTS) | MethylGene Inc. (CA) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008104077-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES (PRMTS) | METHYLGENE INC. (CA) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109896-A1 | FGFR KINASE INHIBITOR AND USE THEREOF | FGFR1, FGFR2, FGFR3 | HSD17B10 1223/4885ALDH1A1 1185/4885TDP1 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.